Tali has over 20 years of extensive experience managing a wide range of complex transactions for life science and biotechnology companies. Her clients span the biotechnology, pharmaceuticals, diagnostics, medical device, health care, and energy sectors, ranging from startups to publicly traded companies with approved drugs and devices. She negotiates deals that advance her clients' commercial interests while mitigating risk.
Her clients work on cutting-edge technologies, including RNA and mRNA therapeutics, antibody and protein therapeutics (including ADCs and CARs), vaccines and vaccine delivery devices, reproductive health care products, oncology platforms, drug discovery platforms leveraging AI, pain relief innovations, brain health solutions, orphan drugs, research reagents, and in vitro and clinical diagnostics. Tali helps clients establish and manage alliances to identify, develop, and commercialize drug candidates, diagnostics, and innovative technologies.
She provides strategic counsel on collaborations, strategic alliances, patent licenses and assignments, research and development agreements, and joint development agreements. Her focus is on keeping critical deals on track, working efficiently, and maximizing business value.
Drawing on her prior experience as in-house corporate counsel for a large, publicly traded biotech company, Tali serves as a trusted business advisor. She understands and accommodates the complexities that can influence intricate deals. Companies rely on her comprehensive transactional expertise and insightful advice to manage investor expectations, control legal costs, address the needs of diverse internal stakeholders, and navigate negotiation challenges. Her clients benefit from her extensive experience and innovative problem-solving approach.
In addition to high-stakes transactions, Tali also handles agreements for day-to-day business operations. These include material transfer and option agreements, clinical supply and research agreements, clinical trial agreements, manufacturing and supply agreements (CDMOs), and service agreements (CROs). She also supports clients by managing and reviewing high-volume routine work, such as confidentiality agreements, customer agreements, and terms and conditions.
Experience
- Innovent Biologics (HKG: 01801), a leading biopharmaceutical company, in its $1.1 billion collaboration agreement with Spero Therapeutics (NASDAQ: SPRO) for a CD40L antibody outside of China.
- Arcturus Therapeutics in a strategic collaboration and manufacturing agreement with Thermo Fisher Scientific for Phase 3 clinical supply, clinical research services, and potential exclusive commercial manufacturing of ARCT-032 for the treatment of cystic fibrosis.
- Antharis Therapeutics, Inc. in its exclusive licensing collaboration with Lonza to combine Lonza’s dual-payload ADC technology with Antharis’ proprietary antibody engineering and target biology platform for the development and commercialization of novel oncology therapeutics.
- Innovent Biologics, a leading biopharmaceutical company pioneering medicines and therapies targeting cancer and other intractable diseases, in its $11.4 billion strategic global collaboration agreement with Takeda, a leading biopharmaceutical company headquartered in Japan.
- Arcturus Therapeutics (NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company, in connection with its partnership agreement with CSL Seqirus for a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines.
- Daré Bioscience in connection with its partnership agreement with Oragonon a global women’s health care company.
- Caladrius Biosciences (NASDAQ: CLBS), a biopharmaceutical company engaged in regenerative medicine and stem cell research, in connection with its merger with Cend Therapeutics — the combined company will operate under the name Lisata Therapeutics (NASDAQ: LSTA).
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH), a biotherapeutics company, in a license agreement with Baylor BioSciences, a life sciences company.
- Immusoft Corporation in its first Big Pharma collaboration in a deal with Takeda valued at $900 million.
- Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots, in connection with its sale to Abbott (NYSE: ABT).
- BlinkBio in out-licensing its patent rights to OS Therapies, a late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors.
- BlinkBio in out-licensing its patent rights to ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors.
- Nuvve Corporation (NASDAQ: NVVE) with respect to its electric school bus and fleet vehicle electrification-as-a-service joint venture with Stonepeak Infrastructure Partners providing up to $750 million in financing.
viewpoints
Getting Ready for the 2023 BIO International Convention: Raising Money Through Creative Partnering
May 31, 2023 | Advisory | By Tali M. Tuchin
Amid a tough equity market and an ebb in investment in the biotech sector, early- or growth-stage companies focused on drug discovery and development may want to spend some time exploring strategic partnerships with other businesses at the 2023 BIO International Convention.
News & Press
podcasts
Mintz On Air: Practical Policies — Trust, Tone, and Trade-Offs: Negotiating Contracts in the AI Age
September 15, 2026 | Podcast | By Jennifer Rubin, Tali M. Tuchin
Mintz On Air explores AI in contract negotiations, covering drafting limits, legal risk, human judgment, trust, and best practices for counsel.
Events & Speaking
ACG San Diego Women's Series
Daring to Be Different: A Founder's Path from Idea to Public Company
Mintz, San Diego, CA
Daring to Be Different: A Founder's Path from Idea to Public Company
ACG San Diego Women's Series
San Diego, CA
American Conference’s Women Leaders in Life Sciences Law
Navigating the Strategic and Geopolitical Realities of China’s Role in Biopharma
San Francisco, CA
TechCon SoCal 2026
Engineering the Next Era of Medicine: AI, mRNA, Gene Therapy, and Advanced Biologics
San Diego, CA
Tips, Tricks, and Traps: Dissecting Confidentiality and Material Transfer Agreements
ACC & Mintz Levin
San Diego, CA
April MCLE - Tech Transfer Agreements: Negotiating with the Government & Academics
ACC & Mintz Levin
San Diego, CA
Recognition & Awards
Recognized by Athena – Pinnacle Award Finalist – Individual in Services (2018)
Best Lawyers in America: IT / Outsourcing Law (2023 – 2025)
Advisor, Life Sciences Cares San Diego
Involvement
- Member, Athena Forum for Executive Women (FEW) group (2010-2021)
- Member, Lawyers Club of San Diego
- Volunteer, Women in Bio, San Diego Chapter (2022-present)
- Co-Founder, JEDA Network (2024-present)
- Member, Advisory Committee, ACI’s West Coast Summit for Women Leaders in Life Sciences Law
